Eporise 2000 Injection contains Recombinant Human Erythropoietin Alfa (2000 IU), a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis, as well as anemia due to chemotherapy in cancer patients. Eporise 2000 Injection is also utilized in certain cases of anemia related to zidovudine therapy in HIV-infected patients and to reduce the need for allogeneic blood transfusions in surgical patients. The administration of Eporise 2000 is typically via subcutaneous or intravenous injection, with dosage individualized based on patient response and hemoglobin levels. Monitoring of hemoglobin concentration, blood pressure, and iron status is essential during therapy to optimize treatment efficacy and minimize adverse effects. Common adverse reactions include hypertension, headache, injection site reactions, and flu-like symptoms. Eporise 2000 Injection should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Proper patient evaluation and adherence to recommended dosing guidelines are critical to ensure safe and effective management of anemia with Eporise 2000 Injection.